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ABSTRACT Finasteride 1 mg, one of the main treatments for male 
androgenetic alopecia (MAGA), may produce sexual dysfunction, 
but young men with MAGA could experience high psychosocial im-
pairment because of changes in body image. Dissatisfaction with 
body image has been linked to an increase in problems with sexual 
function. To date no study has considered the possible effect of psy-
chological impairment on sexual function of men with MAGA. Aim 
of our study was to explore the effect of psychosocial impairment 
produced by hair loss on the sexual function of men with MAGA. Pa-
tients and methods: Cross-sectional design. In total, 190 men with 
MAGA ranging 18-40 years old were recruited from an Internet on-
line community. Participants completed an online survey comprising 
the SKINDEX-29 and the Massachusetts General Hospital Sex Func-
tioning Questionnaire. Individuals with MAGA and moderate to se-
vere psychosocial impairment had a higher risk of sexual dysfunction 
– adjusted odds ratio 2.1 (1.2-4.0; P=0.02) – compared with subjects 
with mild to absent impairment. Sexual desire and sexual arousal 
were the most affected elements of sexual response, but an increase 
in erectile dysfunction and reduced global satisfaction were also re-
ported. We present the first study exploring the influence of MAGA 
psychosocial impairment on sexual function. Men between 18 and 
40 years of age with moderate to severe MAGA psychosocial mor-
bidity were found to have an increased risk of sexual dysfunction. 
Assessment of psychological morbidity and sexual function could be 
critical in patients with MAGA, particularly when considering treat-
ment with finasteride.
KEY WORDS: androgenetic alopecia; male; psychological sexual dys-
function; psychosocial aspects; cross-sectional study
INTRODUCTION
Male androgenetic alopecia (MAGA) is the main 
cause of alopecia in men. Its frequency increases 
with age and affects up to 80% of Caucasian males 
over their lifetime (1). Hair is an important element of 
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body image and identity (2,3). Even partial hair loss 
can lead to psychological disorders and have a nega-
tive impact on quality of life, especially in young indi-
viduals (4-7). Studies of its psychological effects have 
shown that subjects with MAGA feel less physically 
attractive and sexually desirable than normal-haired 
individuals (2,8). Dissatisfaction with body image has 
been linked, in turn, to an increase in problems with 
sexual function (9). Thus, subjects with MAGA could 
present increased problems with sexual function be-
cause of the change in their physical appearance.
Finasteride is the most effective available treat-
ment for MAGA, at the level of evidence 1 and with 
the highest strength of recommendation in present 
guidelines (1). But it is associated with an increased 
risk of sexual dysfunction that can last after treatment 
discontinuation (10). Still, to date no study in the field 
of sexual dysfunction and MAGA has considered the 
possible effect of psychological impairment on sex-
ual function (11,12). The objective of this study is to 
explore the effect of psychosocial impairment due to 
hair loss in the sexual function of men with MAGA.
PATIENTS AND METHODS
Patients
We performed a cross-sectional study between 
February 1, 2013 and May 1, 2013 using an online 
survey. The online survey was hosted in one of the 
biggest Spanish online communities for patients with 
alopecia, “recuperarpelo.com”. It has over 25 000 users 
and over 360 000 discussion topics. After contacting 
the administrative team of www.recuperarpelo.com, 
a discussion topic was published in the forum, ex-
plaining in detail the characteristics and intended use 
of the data of study. Users over 18 years with a MAGA 
diagnosis were invited to complete an online survey. 
The ethics committee of the Hospital Universitario of 
Granada approved this study. Inclusion criteria were 
age between 18 and 40 and Spanish nationality. Ex-
clusion criteria were female sex, treatment for any 
psychiatric, nervous system, or peripheral vascular 
disorders, heart or kidney disease, and history of sur-
gical or radiation treatment for prostate cancer.
Main outcome measures
Our main variables of interest were the presence 
or absence of sexual dysfunction and psychosocial 
impairment secondary to MAGA. For this reason, the 
Massachusetts General Hospital-Sexual Functioning 
Questionnaire (MGH-SFQ) was chosen to assess sex-
ual function (13). The MGH-SFQ is a self-administered 
questionnaire designed to detect problems with sex-
ual function and has been validated in a Spanish pop-
ulation (14). Five items address the different phases of 
the sexual cycle: desire, arousal, orgasm, erection, and 
global sexual satisfaction. Each of these is scored from 
0 (completely reduced) to 4 (normal). High scores in-
dicate better sexual functioning. Scores under 4 in a 
particular item of the questionnaire are indicative 
of dysfunction regarding that element of the sexual 
response. A score under 4 in at least one item of the 
MGH-SFQ was considered sexual dysfunction.
The functional scale of Skindex-29, with the modi-
fication for alopecia suggested by Sung-Hyub Han 
et al., was used to assess the psychosocial impact of 
MAGA (15,16). Skindex-29 is a self-administered ques-
tionnaire, likewise validated in a Spanish population, 
designed to measure the impact of dermatological 
disorders on the quality of life (17). It contains three 
scales: “symptoms” referring to discomfort and physi-
cal limitations, “emotions” or feelings of depression, an-
ger, shame, and fear, and “functioning”, which refers to 
cognitive or social impairment stemming from the psy-
chosocial dimension. We worked with the “functioning” 
scale – our main variable of interest – that we referred 
to as “psychosocial impairment”. Each item is assessed 
using a Likert scale of 0 (never) to 4 (all the time). The 
scale scores are transformed to a linear scale of 100, in 
which 0 represents no impact on health related quality 
of life (HRQOL) and 100 maximum impact on HRQOL 
(16). Various methods have been proposed to catego-
rize the results of Skindex-29 (18,19). We opted to use 
that of Prinsen et al., according to which results ≥32 on 
the “functioning” scale are indicative of moderate to se-
vere psychosocial impairment (r=0.79, sensitivity 0.83, 
specificity 0.88, area under the curve 0.91) (19).
MAGA severity was self-reported by patients in view 
of a diagram depicting the Hamilton-Norwood scale 
provided within the online survey (20). Sociodemo-
graphic and MAGA treatment data were also collected.
Statistical analysis
Descriptive statistics were performed to explore 
the characteristics of the subjects. Continuous data 
were expressed as mean and standard deviation 
(SD). Nominal data were expressed as absolute and 
relative frequencies. Normality of the variables was 
checked by means of the Kolmogorov-Smirnov test. 
The Mann-Whitney Test was used for bivariate com-
parisons. The χ² test or Fisher’s Exact Test were used 
for nominal data when necessary. The main vari-
ables were the presence of impaired sexual function 
(MGH-SFQ under 4 in one item) and moderate to se-
vere psychosocial morbidity (Skindex-29 functioning 
scale equal to or higher than 32) (15,20). Odds ratios 
(OR) with 95% confidence intervals were calculated 
to estimate the strength of association between the 
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identified variables. Significance was set at P<0.05. 
Models of logistic regression were computed by to 
explore the factors associated with sexual dysfunc-
tion. Epidemiological and statistical criteria were used 
to model variable selection (21,22). The effect of each 
exploratory variable in the model and its significance 
were studied: if the variable improved the model fit 
and adequacy (based on likelihood ratio criteria and 
significance of the parameter) it was kept; otherwise, 
the variable was excluded. Different models were fit-
ted with respect to the factors related to sexual dys-
function and psychosocial morbidity. The model was 
checked for pair-wise interaction between covariates, 
and interactions with age were also considered. Po-
tential confounding covariates were studied using a 
change of significance of the parameters in the mod-
el or a change of 30% of its value (23). The goodness 
of fit of the model was assessed using the Hosmer-
Lemeshow test. Analyses were performed using the 
Stata statistical software (version 11.0).
RESULTS
Participants and socio-demographic 
features
Between February 1, 2013 and May 1, 2013, 203 
individuals completed the online survey. Nine partic-
ipants under treatment for anxiety and four partici-
pants under treatment for depression were excluded. 
Therefore, analysis involved 190 Spanish subjects 
with MAGA, aged 18-40. Table 1 and Table 2 summa-
rize and compare the sociodemographic and clini-
cal characteristics of the participants. Most subjects 
showed early stages of MAGA, with 78.9% (150/190) 
reporting I-II severity on the Hamilton-Norwood scale. 
It is also remarkable that 80.0% (152/190) of these in-
dividuals had consulted at least one dermatologist 
because of MAGA. 
Main outcomes
Skindex-29 results showed that 58.4% (111/190) 
of subjects had moderate to severe functional impair-
ment (that is, psychosocial impairment), with a mean 
score of 43.1/100 (28.8), and a median of 43.7/100 
(16.6-66.7) (25th-75th percentile). Subjects with mod-
erate to severe psychosocial impairment had consult-
ed a dermatologist because of MAGA 2.3 times more 
frequently than subjects with mild to absent psycho-
social impairment OR 2.3 (CI 95% 1.1-4.9; P=0.02). 
Results of the MGH-SFQ showed that 41.0% 
(78/190) of subjects had alterations in some element 
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No sexual dysfunction     
N=112
P
Age (years) 26.3 (5.4) 26.5 (5.2) 26.1 (5.5) 0.6
Educational level 0.5
Secondary 28 (14.7) 13 (16.7) 15 (13.4)
Academic 162 (85.0) 65 (83.3) 97 (86.6)
Employment status 0.6
Student 81 (42.6) 33 (42.3) 48 (42.9)
Employed 85 (44.7) 33 (42.3) 52 (46.4)
Unemployed 24 (12.6) 12 (15.4) 12 (10.7)
Place of residence 0.2
Urban 165 (86.8) 65 (83.3) 100 (89.3)
Rural 25 (13.2) 13 (16.7) 12 (10.7)
MAGA severity 0.2
  I 108 (56.8) 50 (64.1) 58 (51.8)
  II 42 (22.1) 15 (19.2) 27 (24.1)
  III≤ 40 (21.1) 13 (16.7) 27 (24.1)
Age of onset (years) 19.5 (3.5) 19.0 (3.1) 19.9 (3.6) 0.03
Finasteride 1mg 74 (38.9) 34 (43.6) 40 (35.7) 0.3
Consulted a 
dermatologist
152 (80.0) 65 (83.3) 87 (77.7) 0.3
Data are expressed as mean (standard deviation) and as number (percentage) Sexual dysfunction: score less than 4 in at least one item of the 
Massachusetts General Hospital Functioning Questionnaire. P values are referred to the comparison of individuals with moderate to severe 
psychological impairment vs. individuals with mild to absent psychological impairment.
of sexual response (Table 2). Those with moderate to 
severe psychosocial impairment due to MAGA expe-
rienced decreased sexual desire, sexual arousal, erec-
tile dysfunction, and diminished global sexual satis-
faction more frequently.
Multivariate analyses
A multivariable model of logistic regression was 
built. Multivariate analysis showed that age OR 1.1 
(CI 95% 1.0-1.2; P=0.02), age of onset of MAGA 0.8 
(CI 95% 0.7-0.9; P=0.001), and psychosocial impair-
ment 2.3 (CI 95% 1.2-4.5; P=0.02) were independent 
risk factors of sexual dysfunction in individuals with 
MAGA (Figure 1). Similar multivariable models were 
built for each element of sexual response (Figure 2). 
Presence of moderate to severe psychosocial impair-
ment implied an independent and significantly higher 
risk of presenting decreased sexual desire, OR 3.3 (CI 
95% 1.5-8.0; P=0.003) and decreased sexual arousal 
OR 3.3 (CI 95% 1.5-7.9; P=0.02) and a non-significant 
increase in erectile dysfunction OR 2.2 (CI 95% 0.9-5.4; 
P=0.06) and diminished global sexual satisfaction OR 
1.8 (CI 95% 0.9-4.0; P=0.08).
DISCUSSION
Key results
The results of our study indicate that individuals 
with MAGA, between 18-40 years of age, with mod-
erate to severe psychosocial impairment (functional 
scale Skindex-29 ≥32) may have an increased risk of 
impaired sexual function as compared with subjects 
with MAGA with mild or no psychosocial distress. This 
risk is significantly increased in relation to sexual de-
sire and arousal, and not significantly related to erec-
tile function and global sexual satisfaction.
Sexual self-consciousness
MAGA can impair social interactions of individu-
als, decreasing self-esteem and increasing public self-
consciousness (2). Public self-consciousness refers 
to a personality predisposition in which the subject 
focuses his attention on observable physical aspects 
of oneself in social interactions (24). Individuals with 
MAGA with increased public self-consciousness could 
feel less attractive and sexually desirable (2). A similar 
perception known as sexual self-consciousness has 
also been described, in which individuals that give 
undue weight to their body image experience an in-
creased risk of sexual dysfunction, especially related 
Total 
N=190
Moderate to severe 
psychological 
impairment 
                      N=111
Mild to absent 
psychological impairment 
                     N=79
P
Sexual dysfunction 78 (41.0) 54 (48.6) 24 (30.4) 0.01
Desire 47 (24.7) 36 (32.4) 11 (13.9) 0.004
Excitement 47 (24.7) 36 (32.4) 11 (13.9) 0.006
Erection 36 (18.9) 26 (23.4) 9 (12.6) 0.06
Orgasm 33 (17.4) 19 (17.1) 14 (17.7) 0.7
Global sexual satisfaction 56 (29.5) 38 (34.2) 18 (22.8) 0.09
Data are expressed as number (percentage). Moderate to severe psychosocial impairment: SKINDEX-29 functioning scale ≥32. Mild to 
absent psychosocial impairment: SKINDEX-29 functioning scale <32. Sexual dysfunction: score less than 4 in at least one item of the 
Massachusetts General Hospital Functioning Questionnaire. P values are referred to the comparison of individuals with moderate to severe 
psychological impairment vs. individuals with mild to absent psychological impairment 
Table 2. Frequencies of sexual dysfunction according to the Massachusetts General Hospital Sex Functioning 
Questionnnaire (MGH-SFQ)
Figure 1. Multivariate logistic regression analysis of poten-
tial factors linked to sexual dysfunction in men with MAGA. 
(MAGA severity: Hamilton-Norwood scale. Moderate to 
severe psyschosocial impairment: SKINDEX-29 functioning 
scale ≥32. Variables included in the model: age, educational 
level, employment status, place of residence, MAGA sever-
ity, age of onset, finasteride 1 mg, consulted a dermatolo-
gist, moderate to severe psyschosocial impairment.)
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to sexual desire and global sexual satisfaction, and 
probably related to erectile function as well (9,25-28). 
Individuals with high levels of sexual self-conscious-
ness experience anxiety about their physical appear-
ance during sexual activity; the fact that they have 
difficulty relaxing and focusing on sex eventually 
leads to problems with sexual function (9). 
Our group of subjects with MAGA with moder-
ate to severe psychosocial impairment includes indi-
viduals experiencing high public self-consciousness, 
which implies heightened body awareness during so-
cial interactions (public self-consciousness) and also 
during sexual activity (sexual self-consciousness) that 
could lead to an increase in sexual dysfunctions (2,9). 
Our results showed an independent and significant 
association between psychological impairment and 
decreased sexual desire and arousal, which agrees 
with the hypothesis of sexual self-consciousness. The 
correlation between earlier MAGA onset and sexual 
dysfunction also supports this hypothesis. Young in-
dividuals prone to placing more importance on phys-
ical appearance would be more insecure regarding 
changes in body appearance and hence more vulner-
able to psychological consequences (26).
Finasteride
According to the available scientific evidence, we 
observed an increase (non-significant) in alterations 
of the different elements of sexual response associ-
ated with the use of finasteride 1 mg (10). Finasteride 
1 mg prescribing information states: “The most com-
mon adverse reactions, reported in ≥1% of patients 
treated with finasteride 1 mg and greater than in 
patients treated with placebo are: decreased libido, 
erectile dysfunction and ejaculation disorder” (10). 
Decreased sexual desire (libido) and arousal are the 
more frequent sexual dysfunctions associated with 
the use of finasteride (29,30). Our results showed that 
psychosocial impairment was significantly associated 
with a decreased sexual desire and arousal, indepen-
dently from the use of finasteride 1 mg (Figure 2). No 
other study to date in the field of sexual dysfunction 
and finasteride has considered the potential impact 
of psychological variables in this relationship. Could 
psychological impairment confound the relationship 
between finasteride and sexual dysfunction in men 
with MAGA? We therefore believe that conducting 
further studies including variables for assessing psy-
chological impact is a high priority.
Generalizability
Regarding to the external validity of our sample, 
we want to emphasize that nearly 80% of the par-
ticipants of our study had consulted at least one der-
matologist regarding their MAGA. The fact that these 
individuals participated in an online community for 
alopecia suggests they are more concerned about 
the impact of alopecia on their everyday life. Seek-
ing dermatological care for MAGA is factor associated 
with greater psychosocial impairment (2,3,15). In our 
interpretation, users of an alopecia Internet com-
munity may share a profile – young, Internet user, 
concerned about the MAGA – and be more likely to 
consult a dermatologist more readily than a sample 
of the general population.
Limitations
We acknowledge some methodological limita-
tions in our study that should be considered when 
interpreting the results: 1) Sample size is limited. A 
larger sample could make some borderline associa-
tions, like psychosocial impairment and erectile dys-
function, significant. 2) The recruitment of patients 
through an online survey may have resulted in a dif-
ferential selection bias, as participants could have a 
greater awareness of MAGA and its impact (3). For 
the purposes of our study, however, the method of 
sample selection was very suitable in that online re-
cruitment led us to a large sample of individuals with 
intense MAGA-related psychological impact. 3) Non-
Spanish subjects were not included because cultural 
differences can influence psychological constructs of 
MAGA and sexual function, thereby limiting the ex-
ternal validity of results (22,31,32). 4) Subjects over 
40 years of age were not included in the analysis, 
which limits the external validity of our results. Still, 
we believe that the population aged 18-40 is the 
most important age group in terms of willingness 
Figure 2. Multivariate logistic regression analysis exploring 
the effect of moderate to severe psychosocial impairment 
in dysfunctions of the different phases of human sexual re-
sponse in men with MAGA. (Variables included in the model: 
age, educational level, employment status, place of resi-
dence, MAGA severity (Hamilton-Norwood scale), age of 
onset, finasteride 1 mg, consulted a dermatologist.) 
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to find treatment and concern about quality of life 
impact regarding MAGA (2,21,22,32,33). Finasteride 
clinical trials have been performed with individuals 
in this age range (10). 5) The diagnosis and degree of 
MAGA were not reported by a dermatologist, yet the 
self-reported diagnosis of MAGA, as in our study, has 
proven valid for diagnosis and disease severity assess-
ment (3,20,34). 6) Due to the cross-sectional design of 
the study, assumptions and sense of causal relations 
should be taken with caution.
Considering these limitations, we believe the re-
sults of this study should serve as a wake-up call to 
the dermatology community to reconsider the im-
portance of psychosocial impairment in patients with 
MAGA in view of its potential impact on sexual func-
tion. Primarily, though finasteride is the most effec-
tive and widespread treatment for MAGA to date, it 
is associated with changes in sexual function (1,10-
12). Thus, identification of subjects with MAGA with 
a high-risk profile of sexual dysfunction could have 
important therapeutic implications.
CONCLUSION
In conclusion, we present the results of the first 
study investigating the influence of psychosocial im-
pairment produced by MAGA on male sexual func-
tion. Men between 18 and 40 years of age with mod-
erate to severe MAGA and psychosocial impairment 
(functional scale Skindex-29 ≥32) have an increased 
risk of sexual dysfunction, particularly in terms of de-
sire and arousal. Therefore, we encourage the inclu-
sion of instruments to assess psychological morbidity 
and sexual function in general practice. In the case 
of initiating therapy with finasteride or in the pres-
ence of sexual adverse effects during treatment, this 
could be especially important. Future studies should 
explore the association between sexual dysfunction 
and inhibitors of 5-alpha reductase.
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